Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 43

Sort by

Sort Order Select

Journal Articles

Long-Term Follow-up of Patients with Aplastic Anemia Enrolled in Phase 2/3 Trials of Immunosuppressive Therapy Plus Romiplostim As a First-Line Treatment: Two-Year Interim Analysis

Blood (2024) 144 (Supplement 1): 1310.

https://doi.org/10.1182/blood-2024-193925

Published: 2024

Journal Articles

Efficacy and Safety of Long-Term Romiplostim Use for Refractory Aplastic Anemia

Blood (2022) 140 (Supplement 1): 8634–8637.

https://doi.org/10.1182/blood-2022-162895

Published: 2022

Journal Articles

Phase 1 Study of Alvocidib (DSP-2033) in Combination with Cytarabine/Mitoxantrone (ACM) or Cytarabine/Daunorubicin (A+7+3) in Japanese Patients (Pts) with Acute Myeloid Leukemia (AML)

Yasuyoshi Morita, Takayuki Ikezoe, MD PhD, Kiyoshi Ando, Masahiro Onozawa, Takahisa Yamane, MD PhD, Naoko Hosono, MD PhD, Toru Kiguchi, Hiromi Iwasaki, Toshihiro Miyamoto, MD PhD, Miho Kasai, Saori Sugimoto, Yasushi Miyazaki, MD PhD, Masahiro Kizaki, MD, Koichi Akashi, MD PhD

Blood (2020) 136 (Supplement 1): 34–35.

https://doi.org/10.1182/blood-2020-134078

Published: 2020

Journal Articles

Prognostic Effects of Pretreatment Statuses at Diagnosis in Patients with Chronic Myeloid Leukemia: Results of the New Target Observational Study 1

Takaaki ONO, MD PhD, Naoto Takahashi, MD PhD, Masahiro Kizaki, MD, Tatsuya Kawaguchi, MD, Ritsuro Suzuki, MD PhD, Kazuhito Yamamoto, Kazunori Ohnishi, MD, Tomoki Naoe, MD PhD, Itaru Matsumura, MD PhD

Blood (2019) 134 (Supplement_1): 4149.

https://doi.org/10.1182/blood-2019-122092

Published: 2019

Journal Articles

Second-Generation Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia with Additional Chromosomal Abnormalities

Naoto Takahashi, MD PhD, Tomoko Yoshioka, MD, Masahiro Kizaki, MD, Tatsuya Kawaguchi, MD, Ritsuro Suzuki, MD PhD, Kazuhito Yamamoto, Kazunori Ohnishi, MD, Tomoki Naoe, MD PhD, Itaru Matsumura, MD PhD

Blood (2019) 134 (Supplement_1): 1640.

https://doi.org/10.1182/blood-2019-123337

Published: 2019

Journal Articles

Comparison of the Clinical Outcomes of Nilotinib and Dasatinib Therapies in Newly Diagnosed Patients in the Chronic Phase of Chronic Myeloid Leukemia: A Retrospective Analysis

Noriyoshi Iriyama, MD PhD, Kei-Ji Sugimoto, Eriko Sato, MD PhD, Tomoiku Takaku, MD PhD, Michihide Tokuhira, Tomonori Nakazato, MD PhD, Maho Ishikawa, MD, Hiroyuki Fujita, MD PhD, Yuta Kimura, MD, Isao Fujioka, MD, Norio Asou, MD PhD, Masahiro Kizaki, MD PhD, Norio Komatsu, MD PhD, Yoshihiro Hatta, MD PhD, Tatsuya Kawaguchi, MD PhD

Blood (2018) 132 (Supplement 1): 4268.

https://doi.org/10.1182/blood-2018-99-111732

Published: 2018

Journal Articles

The Absolute Count of Lymphocytes Is a Strong Predictive Factor for Relapse/Regrowth Events and Outcomes in Patients with Regressive Methotrexate-Associated Lymphoproliferative Disorders

Michihide Tokuhira, Yuta Kimura, MD, Yuka Tanaka, MD, Yasuyuki Takahashi, MD PhD, Tatsuki Tomikawa, MD PhD, Junichi Watanabe, MD PhD, Tomoe Anan-Nemoto, MD PhD, Morihiko Sagawa, MD PhD, Shuji Momose, MD PhD, Morihiro Higashi, MD PhD, Tabayashi Takayuki, MD PhD, Reiko Nakaseko, MD PhD, Jun-ichi Tamaru, MDPhD, Masahiro Kizaki, MDPhD

Blood (2018) 132 (Supplement 1): 1589.

https://doi.org/10.1182/blood-2018-99-114382

Published: 2018

Journal Articles

Efficacy and Safety of Tyrosine Kinase Inhibitors for Treatment of Newly Diagnosed Chronic Myeloid Leukemia: Results Using Data Obtained with the New Target System from the Japanese Registry

Naoto Takahashi, MD, Masahiro Kizaki, MDPhD, Masatomo Miura, PhD, Tatsuya Kawaguchi, MD PhD, Ritsuro Suzuki, MD PhD, Kazuhito Yamamoto, MDPhD, Kazunori Ohnishi, MD PhD, Itaru Matsumura, MD, Tomoki Naoe, MD PhD, Koichi Akashi, MD PhD

Blood (2018) 132 (Supplement 1): 1751.

https://doi.org/10.1182/blood-2018-99-111680

Published: 2018

Journal Articles

Efficacy and Safety of Romiplostim in Patients with Acquired Aplastic Anemia Ineligible or Refractory to Immunosuppressive Therapy: Interim Analysis of Phase 2/3 Clinical Trial

Blood (2018) 132 (Supplement 1): 1306.

https://doi.org/10.1182/blood-2018-99-112478

Published: 2018

Journal Articles

Dual Targeting of Cell-Cycle Checkpoint Kinase and Unfolded Protein Response As a Novel Therapeutic Approach for High-Risk Multiple Myeloma with TP53 Deletion or Mutations

Yuka Tanaka, MD, Takayuki Tabayashi, MD PhD, Yasuyuki Takahashi, MD PhD, Yuta Kimura, MD, Tatsuki Tomikawa, MD PhD, Junichi Watanabe, MD PhD, Tomoe Anan-Nemoto, MD PhD, Morihiko Sagawa, MD PhD, Reiko Watanabe, MD PhD, Michihide Tokuhira, Masahiro Kizaki, MD PhD

Blood (2018) 132 (Supplement 1): 5613.

https://doi.org/10.1182/blood-2018-99-116247

Published: 2018

Journal Articles

Successful MPB Therapy Followed By Bortezomib Maintenance for Non-Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma: Japanese Phase 2 Study - Broad-J Study

Blood (2017) 130 (Supplement 1): 5432.

https://doi.org/10.1182/blood.V130.Suppl_1.5432.5432

Published: 2017

Journal Articles

Impact of the Duration of Methotrexate Administration and the Specific HLA Alleles on the Regressive Methotrexate-Induced Lymphoproliferative Disorders

Michihide Tokuhira, MD, Shuntaro Saito, MD, Ayumi Okuyama, MD, Katsuya Suzuki, MD, Morihiro Higashi, MD, Shuju Momose, MD, Takayuki Shimizu, MD, Takehiko Mori, MD PhD, Tomoe Anan-Nemoto, MD, Koichi Amano, MD, Shinichiro Okamoto, MD PhD, Tsutomu Takeuchi, MD, Jun-ichi Tamaru, MDPhD, Masahiro Kizaki, MDPhD

Blood (2017) 130 (Supplement 1): 4024.

https://doi.org/10.1182/blood.V130.Suppl_1.4024.4024

Published: 2017

Journal Articles

Clinicopathological Study of Methotrexate-Associated Lymphoproliferative Disorders in Rheumatoid Arthritis Patients: Histological Classification and Predictive Factors for Disease Progression

Daisuke Kurita, MD, Hiroaki Miyoshi, MDPhD, Ayako Ichikawa, MDPhD, Yuya Sasaki, MD, Keisuke Kawamoto, MDPhD, Joji Shimono, MD, Masao Matsuoka, MDPhD, Masahiro Kizaki, MDPhD, Masao Seto, MD PhD, Jun-ichi Tamaru, MDPhD, Michihide Tokuhira, MD, Koichi Ohshima, MDPhD

Blood (2017) 130 (Supplement 1): 4168.

https://doi.org/10.1182/blood.V130.Suppl_1.4168.4168

Published: 2017

Journal Articles

CD14-CD15+, Possible Cells Are Potent Myeloid-Derived Suppressor Cells, Which Affect the Pathogenesis of Induction and Regression in Methotrexate-Mediated Lymphoproliferative Disorders

Michihide Tokuhira, MD PhD, Shuntaro Saito, MD, Yuka Tanaka, MD, Yasuyuki Takahashi, MD, Yuta Kimura, MD, Tatsuki Tomikawa, MD, Tomoe Anan, MD, PhD, Shuji Momose, MD PhD, Morihiro Higashi, MD, PhD, Takayuki Shimizu, MD PhD, Takehiko Mori, MD PhD, Takayuki Tabayashi, MD PhD, Reiko Watanabe, MD PhD, Jun-ichi Tamaru, MD, PhD, Shinichiro Okamoto, MD PhD, Masahiro Kizaki, MD PhD

Blood (2016) 128 (22): 2946.

https://doi.org/10.1182/blood.V128.22.2946.2946

Published: 2016

Journal Articles

Inhibition of WEE1 Induces Cell Death of Both Bortezomib- and Lenalidomide-Resistant Multiple Myeloma Cells: A Novel Therapeutic Approach Targeting Cell-Cycle Checkpoint Kinase

Takayuki Tabayashi, MD PhD, Yuka Tanaka, MD, Yasuyuki Takahashi, MD, Yuta Kimura, MD, Tatsuki Tomikawa, MD, Morihiko Sagawa, MD PhD, Tomoe Anan-Nemoto, MDPhD, Reiko Watanabe, MD PhD, Michihide Tokuhira, MD PhD, Masahiro Kizaki, MD PhD

Blood (2016) 128 (22): 3256.

https://doi.org/10.1182/blood.V128.22.3256.3256

Published: 2016

Journal Articles

Preliminary Results from a Phase 1/2 Study of DSP-7888, a Novel WT1 Peptide-Based Vaccine, in Patients with Myelodysplastic Syndrome (MDS)

Shigesaburo Miyakoshi, MD PhD, Kensuke Usuki, MD PhD, Itaru Matsumura, MD PhD, Yasunori Ueda, MD PhD, Hiromi Iwasaki, MD PhD, Toshihiro Miyamoto, MD PhD, Makoto Origuchi, Shuzo Tagashira, Ichiro Naoi, Tomoki Naoe, MD PhD, Masahiro Kizaki, MD PhD, Yuji Heike, MD PhD, Koichi Akashi, MD PhD, Yasushi Miyazaki, MD PhD

Blood (2016) 128 (22): 4335.

https://doi.org/10.1182/blood.V128.22.4335.4335

Published: 2016

Journal Articles

The Efficacy and Safety of Weekly Bortezomib Containing VMP Followed By Bortezomib Maintenance Therapy in Unfit or Frail Multiple Myeloma Patients

Naoki Takezako, MD PhD, Michihide Tokuhira, MD PhD, Naohiro Sekiguchi, MD PhD, Yuya Kurihara, MD, Kenichi Ito, MD, Miwa Kurimoto, MD PhD, Kenshi Suzuki, MD PhD, Masahiro Kizaki, MD PhD

Blood (2016) 128 (22): 4529.

https://doi.org/10.1182/blood.V128.22.4529.4529

Published: 2016

Journal Articles

Novel Therapeutic Approach to Overcome Both Bortezomib- and Lenalidomide-Resistant Multiple Myeloma By Targeting TOPK/PBK

Takayuki Tabayashi, MD PhD, Yasuyuki Takahashi, MD, Yuta Kimura, MD, Tatsuki Tomikawa, MD, Tomoe Nemoto-Anan, MD PhD, Reiko Watanabe, MD PhD, Michihide Tokuhira, MD PhD, Masahiro Kizaki, MD PhD

Blood (2015) 126 (23): 1763.

https://doi.org/10.1182/blood.V126.23.1763.1763

Published: 2015

Journal Articles

A Phase 1/2 Study of WT1 Peptide Cancer Vaccine WT4869 in Patients with Myelodysplastic Syndromes (MDS)

Takahiro Suzuki, MD PhD, Yasunori Ueda, MD PhD, Michinori Ogura, MD PhD, Toshiki Uchida, MD PhD, Keiya Ozawa, MD PhD, Shigesaburo Miyakoshi, MDPhD, Tomoki Naoe, MD PhD, Makoto Murata, MD PhD, Masahiro Kizaki, MD PhD, Naokuni Uike, MD, Yasunobu Abe, MD PhD, Michihiro Hidaka, MD PhD, Shuzo Tagashira, Satoru Tsuchiya, Kazuma Ohyashiki, MD PhD, Yasushi Miyazaki, MD PhD

Blood (2015) 126 (23): 2868.

https://doi.org/10.1182/blood.V126.23.2868.2868

Published: 2015

Journal Articles

Targeting the Wnt/β-Catenin Signaling Pathway in Multiple Myeloma: A Possible New Therapeutic Approach to Overcome Bortezomib-Resistance

Takayuki Tabayashi, MD, Yasuyuki Takahashi, MD, Yuta Kimura, MD, Tatsuki Tomikawa, MD, Morihiko Sagawa, MD PhD, Tomoe Nemoto, MD, Reiko Watanabe, MD PhD, Michihide Tokuhira, MD, Shigehisa Mori, MD, Masahiro Kizaki, MD

Blood (2014) 124 (21): 3372.

https://doi.org/10.1182/blood.V124.21.3372.3372

Published: 2014

NARROW

Long-Term Follow-up of Patients with Aplastic Anemia Enrolled in Phase 2/3 Trials of Immunosuppressive Therapy Plus Romiplostim As a First-Line Treatment: Two-Year Interim Analysis

Efficacy and Safety of Long-Term Romiplostim Use for Refractory Aplastic Anemia

Phase 1 Study of Alvocidib (DSP-2033) in Combination with Cytarabine/Mitoxantrone (ACM) or Cytarabine/Daunorubicin (A+7+3) in Japanese Patients (Pts) with Acute Myeloid Leukemia (AML)

Prognostic Effects of Pretreatment Statuses at Diagnosis in Patients with Chronic Myeloid Leukemia: Results of the New Target Observational Study 1

Second-Generation Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia with Additional Chromosomal Abnormalities

Comparison of the Clinical Outcomes of Nilotinib and Dasatinib Therapies in Newly Diagnosed Patients in the Chronic Phase of Chronic Myeloid Leukemia: A Retrospective Analysis

The Absolute Count of Lymphocytes Is a Strong Predictive Factor for Relapse/Regrowth Events and Outcomes in Patients with Regressive Methotrexate-Associated Lymphoproliferative Disorders

Efficacy and Safety of Tyrosine Kinase Inhibitors for Treatment of Newly Diagnosed Chronic Myeloid Leukemia: Results Using Data Obtained with the New Target System from the Japanese Registry

Efficacy and Safety of Romiplostim in Patients with Acquired Aplastic Anemia Ineligible or Refractory to Immunosuppressive Therapy: Interim Analysis of Phase 2/3 Clinical Trial

Dual Targeting of Cell-Cycle Checkpoint Kinase and Unfolded Protein Response As a Novel Therapeutic Approach for High-Risk Multiple Myeloma with TP53 Deletion or Mutations

Successful MPB Therapy Followed By Bortezomib Maintenance for Non-Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma: Japanese Phase 2 Study - Broad-J Study

Impact of the Duration of Methotrexate Administration and the Specific HLA Alleles on the Regressive Methotrexate-Induced Lymphoproliferative Disorders

Clinicopathological Study of Methotrexate-Associated Lymphoproliferative Disorders in Rheumatoid Arthritis Patients: Histological Classification and Predictive Factors for Disease Progression

CD14-CD15+, Possible Cells Are Potent Myeloid-Derived Suppressor Cells, Which Affect the Pathogenesis of Induction and Regression in Methotrexate-Mediated Lymphoproliferative Disorders

Inhibition of WEE1 Induces Cell Death of Both Bortezomib- and Lenalidomide-Resistant Multiple Myeloma Cells: A Novel Therapeutic Approach Targeting Cell-Cycle Checkpoint Kinase

Preliminary Results from a Phase 1/2 Study of DSP-7888, a Novel WT1 Peptide-Based Vaccine, in Patients with Myelodysplastic Syndrome (MDS)

The Efficacy and Safety of Weekly Bortezomib Containing VMP Followed By Bortezomib Maintenance Therapy in Unfit or Frail Multiple Myeloma Patients

Novel Therapeutic Approach to Overcome Both Bortezomib- and Lenalidomide-Resistant Multiple Myeloma By Targeting TOPK/PBK

A Phase 1/2 Study of WT1 Peptide Cancer Vaccine WT4869 in Patients with Myelodysplastic Syndromes (MDS)

Targeting the Wnt/β-Catenin Signaling Pathway in Multiple Myeloma: A Possible New Therapeutic Approach to Overcome Bortezomib-Resistance

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only